We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Loss of Notch1 Signaling Leads to Skin Cancer in Mouse Model

By LabMedica International staff writers
Posted on 16 Jul 2009
Researchers using a line of genetically engineered mice lacking the Notch1 signaling protein in some skin cells have found that a state of persistent inflammation can lead to the generation of skin cancers from both normal cells and those lacking the Notch1 gene.

Investigators at Washington University School of Medicine (St. More...
Louis, MO, USA) created a line of mice with both normal and Notch1 null skin cells. These animals developed thickened and inflamed patches of skin due to an increased number of blood vessels and local inflammation, which were a result of missing Notch1 signaling in some of the cells. Interestingly, these animals were prone to developing skin papillomas that originated from both normal and Notch 1 null skin cells. About 10% of these papillomas progressed to basal cell carcinomas.

While Notch1 is generally considered a tumor-suppressing gene in skin cells, Notch1 null patches of skin encouraged angiogenesis and the production of growth factors. The persistent expression of these factors provided cells with nutrients and proliferation signals that promoted tumor formation in the mutant skin tissue and in neighboring normal skin cells with active Notch1 signaling.

"The chronic skin condition in the mice led to the growth of skin tumors," said senior author Dr. Raphael Kopan, professor of developmental biology and dermatology at Washington University School of Medicine. "And what we learned from this process fit very well with the emerging realization that a tumor's surroundings play a critical role in its development. The study suggests that as researchers develop drugs, they should be mindful of their potential effect on the skin, particularly those that cause chronic damage to skin integrity. Studies like ours help define the range of possible complications in drug design and help tailor therapies to avoid them."

"It is very reasonable to assume that chronic wounds in a variety of tissues have similar characteristics," said Dr. Kopan. "The skin of these mice is easy to monitor and will give us the ability to further analyze tumor promotion and find answers that might apply to any chronic wound."

Related Links:

Washington University School of Medicine



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.